对EGFR敏感突变肺腺癌TKI治疗后轻微进展医生对策的调查

Investigation of physician countermeasures for mild progression after treatment with EGFR-TKI in lung adenocarcinoma

    摘要
  • 摘要:
    目的 了解医生对表皮生长因子受体酪氨酸激酶抑制剂（epithelial growth factor receptor tyrosine kinase inhibitor，EGFR-TKI）治疗后轻微进展的发生率和治疗策略的看法，为优化后续治疗对策提供建议。
    方法 采用方便抽样的方法，面向全国肿瘤及呼吸科医生实施网络问卷调查。
    结果 回收有效问卷584份，所有医生均关注到EGFR-TKI治疗后出现的肿瘤轻微进展，对此选择的应对策略包括维持原TKI治疗、原TKI基础上的增加其他治疗、更换方案和实施二次组织活检，其中选择在原TKI基础上增加治疗者最多。
    结论 临床医生已重视疾病稳定（stable disease，SD）中靶病灶增大的情况，并多选择在原TKI基础上增加治疗应对，这可为今后的指南制定提供参考，但仍需大样本前瞻性临床研究寻找更合适的协同治疗方案。

     

    Abstract:
    Objective To investigate the views of doctors on the incidence and treatment tactics of mild progression after epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in lung adenocarcinoma and provide suggestions to optimize the countermeasure strategies.
    Methods  Convenience sampling was used to conduct an online questionnaire survey for doctors specializing in oncology and respiratory diseases.
    Results  584 valid questionnaires were collected, and all the doctors expressed concerns regarding mild tumor progression after EGFR-TKI treatment. The coping strategies included maintaining the original TKI treatment, adding other treatments to the original TKI, changing the regimen, and performing secondary tissue biopsy, among which, most doctors chose to add other treatments to the original TKI.
    Conclusions  Doctors have noticed the enlargement of target lesions in still stable disease (SD) and most frequently chose to add other treatments to the original TKI as a coping strategy. This finding can provide a reference for framing future guidelines for large sample prospective clinical studies that are needed to find the most effective synergistic treatment options.

     

    • HTML全文
    • 参考文献(21)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回